<DOC>
	<DOCNO>NCT02121990</DOCNO>
	<brief_summary>The purpose study test safety drug olaparib different dose level . It give standard initial chemotherapy cancer well drug call bevacizumab .</brief_summary>
	<brief_title>Dose-Escalation Study Intraperitoneal ( IP ) Cisplatin , IV/IP Paclitaxel , IV Bevacizumab , Oral Olaparib Newly Diagnosed Ovarian , Primary Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Subjects histologic diagnosis epithelial ovarian carcinoma , primary peritoneal carcinoma , fallopian tube carcinoma , follow initial surgery . All subject must appropriate surgery ovarian , primary peritoneal , fallopian tube carcinoma appropriate tissue available histologic evaluation confirm diagnosis stage . Pathology must verify Memorial SloanKettering Cancer Center . Patients initial cytoreduction surgery perform outside hospital eligible protocol . Patients follow histologic cell type eligible : High grade serous adenocarcinoma Endometrioid adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial adenocarcinoma Adenocarcinoma otherwise specify ( N.O.S . ) Carcinosarcoma Subjects must Karnofsky Performance Status ( KPS ) ≥ 70 % . Subjects must enter 12 week postoperatively . Subjects must agree undergo genetic counseling BRCA testing . Patients expansion cohort must germline BRCA 1 2 mutation . Physical Laboratory Test Findings PT international normalize ratio ( INR ) ≤1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin ) PTT ≤ 1.5 time upper limit normal . Bone marrow function : Absolute neutrophil count ( ANC ) ≥ 1,500/mcL Platelets ≥ 100,000/mcL Renal function : Creatinine ≤ 1.5 mg/dl Hepatic function : Bilirubin ≤ 1.5 x ULN AST ALT ≤ 3 x ULN Neurologic function : Neuropathy ( sensory ) ≤ CTC Grade 1 Urine Protein Creatinine : Urine protein creatinine ( UPC ) ratio must &lt; 1.0 gm . If UPC ratio ≥1 , collection 24hour urine measurement urine protein recommend * UPC ratio spot urine estimation 24 urine protein excretion UPC ratio 1 roughly equivalent 24hour urine protein 1 gm . UPC ratio calculate use one follow formula : 1 . [ urine protein ] / [ urine creatinine ] protein creatinine report mg/dL 2 . [ ( urine protein ) x0.088 ] / [ urine creatinine ] urine creatinine report mmol/L *The UPCR find correlate directly amount protein excreted 24 hour urine collection . Specifically , UPCR 1.0 equivalent 1.0 gram protein 24 hour urine collection . Obtain least 4 ml random urine sample sterile container ( 24 hour urine ) . Send sample lab request urine protein creatinine level [ separate request ] . The lab measure protein concentration ( mg/dL ) creatinine concentration ( mg/dL ) . The UPCR derive follow : protein concentration ( mg/dL ) /creatinine ( mg/dL ) . Patients must UPCR &lt; 1.0 allow participation study . Patients childbearing potential must negative serum pregnancy test prior study entry practice effective form contraception study least 6 month receive final treatment bevacizumab . Patients must Intraperitoneal ( IP ) port place . If patient IP port , must willing undergo surgical placement one . Subjects current diagnosis epithelial ovarian tumor low malignant potential ( borderline carcinoma ) eligible . Patients synchronous primary endometrial cancer past history endometrial cancer , unless follow condition meet : Stage great IB No superficial myometrial invasion No vascular lymphatic invasion No poorly differentiate subtypes , include papillary serous , clear cell , FIGO Grade 3 lesion . Subjects receive prior radiotherapy portion abdominal cavity pelvis exclude . Prior intravaginal brachytherapy permit . Prior radiation localize cancer breast , head neck , skin permit , provide complete 3 year prior enrollment , subject remain free recurrent metastatic disease . Patients receive prior chemotherapy abdominal pelvic tumor exclude . Patients receive neoadjuvant chemotherapy prior initial debulking exclude . Patients may receive prior adjuvant chemotherapy localize breast cancer . With exception nonmelanoma skin cancer specific malignancy note , subject invasive malignancy ( ) evidence cancer present within last 3 year whose previous cancer treatment contraindicate protocol therapy exclude . Patients receive prior bevacizumab ( VEGF target agent ) prior PARP inhibitor . Subjects acute hepatitis . Subjects active infection require parenteral antibiotic . &gt; Grade 1 hearing loss tinnitus Patients pregnant nursing . Patients age 18 . Patients clinical symptom sign gastrointestinal obstruction , require parenteral hydration nutrition , require drainage gastrostomy tube and/or impairment limit ability take oral medication . Patients serious nonhealing wound , ulcer , bone fracture include history abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day . Patients granulate incision heal secondary intention evidence fascial dehiscence infection eligible require weekly wound examination . Patients active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel . Patients history evidence upon physical examination CNS disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage within six month first date treatment study . Patients clinically significant cardiovascular disease include Uncontrolled hypertension , define systolic &gt; 150 mm Hg diastolic &gt; 90 mm Hg . Myocardial infarction unstable angina &lt; 6 month prior registration . New York Heart Association ( NYHA ) Class II higher congestive heart failure Serious cardiac arrhythmia require medication . CTEP CTCAE Version 4.0 , Grade 2 high peripheral ischemia [ brief ( &lt; 24 hr ) episode ischemia manage nonsurgically without permanent deficit ] . Core biopsy minor surgical procedure ( exclude placement vascular access device , paracentesis , and/or thoracentesis ) within 7 day prior first date bevacizumab therapy . Patients know hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody . Patients receive medication substance strong inhibitor inducer CYP3A4 . Lists include medication substance know potential interact enzyme .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>( IP ) Cisplatin</keyword>
	<keyword>IV/IP Paclitaxel</keyword>
	<keyword>IV Bevacizumab</keyword>
	<keyword>Oral Olaparib ( AZD2281 )</keyword>
	<keyword>Optimally Debulked</keyword>
	<keyword>Stage II/III</keyword>
	<keyword>Ovary</keyword>
	<keyword>Pertoneum</keyword>
	<keyword>10-220</keyword>
</DOC>